Parkinson’s disease treatment pipeline holds significant potential for patients and investors

The Parkinson’s disease treatment pipeline presents a distinctly more promising landscape than the current market, which is burdened with unmet needs and a lack of disease-modifying drugs, says business intelligence provider GBI Research


(Photo Courtesy:

According to the company's latest report, the current Parkinson's disease treatment market relies on neuromodulators, and although levodopa and dopaminergic treatments can be used to relieve symptoms, there is not an agent that has demonstrated neuro-protective properties to prevent or at least significantly slow neuronal cell death.

However, Ms Angel Wong, Senior Analyst for GBI Research, states that the pipeline for the disease is highly active, consisting of 365 programs across all stages of development, and a diverse range of molecular targets.

Ms Wong says: "The Parkinson's disease treatment pipeline is characterized by a high level of innovation compared to the central nervous system segment and the industry as a whole, with 43% of all pipeline programs with disclosed molecular targets being first-in-class.

"While neuromodulators remain dominant in the pipeline, there are a number of targets which address different pathogenic mechanisms underlying neuro-degeneration in Parkinson's disease. This demonstrates a shift from traditional symptomatic treatments to disease-modifying therapies."

The analyst adds that as the majority of potentially disease-modifying treatments are in the early stages of development, they are expected to fulfill a huge unmet need in the Parkinson's disease treatment market in the long term.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email